Boston Scientific Foundation

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

4C Medical Technologies Inc., established in 2015 and headquartered in Maple Grove, Minnesota, is a medical device company specializing in therapies for structural heart diseases. Its primary product, AltaValve, treats mitral regurgitation via supra-annular positioning and atrial-only fixation, preserving the native mitral valve and left ventricle while eliminating issues associated with traditional transcatheter mitral valve replacement technologies.

SoniVie is a medical device company focused on developing innovative solutions for the treatment of pulmonary hypertension. The company has created a minimally invasive denervation device that is designed to be inserted into the pulmonary artery through a catheterization procedure. This advanced technology selectively targets and damages the nerves associated with pulmonary hypertension, while preserving the integrity of the vessel walls and surrounding tissues. By enabling physicians to perform denervation procedures with greater precision, SoniVie aims to improve treatment options and outcomes for patients suffering from this serious condition.

Bolt Medical is a medical device company that specializes in the development of innovative healthcare solutions. Its flagship product is the investigational Bolt IVLTM System, a laser-based intravascular lithotripsy catheter designed for coronary and peripheral interventional procedures. This device offers consistent acoustic output and advantages over existing platforms, potentially improving recovery for patients with moderate to severe calcified arterial disease.

Intera Oncology is a medical technology company focused on enhancing the survival rates and quality of life for patients with colorectal cancer and cholangiocarcinoma. Based in Wellesley, Massachusetts, the company was established in 2019 and specializes in developing innovative drug delivery systems. Intera Oncology acquired certain oncology and neuromodulation drug delivery products from Johnson & Johnson, including accessories for Codman 3000, MedStream, and Model 400/500 pumps. Their flagship device is a continuous flow pump designed to deliver chemotherapy directly to the liver, aiming to prevent the spread of cancer metastases in this organ.

Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market.

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, founded in 2017. The company is focused on developing a novel treatment aimed at stabilizing the growth of mid-sized abdominal aortic aneurysms and preventing their rupture. Nectero Medical's innovative approach involves delivering a compound with a stabilizing agent directly to the aneurysm site, which inhibits further breakdown of the vessel wall and strengthens it. This treatment enables patients to undergo earlier intervention safely, potentially delaying or eliminating the need for major endovascular or surgical repairs.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

Acotec Scientific is an interventional medical device company specializing in vascular treatment solutions. The company's portfolio includes Drug-coated Balloons (DCB) and Percutaneous Transluminal Angioplasty Balloon Catheter (PTA), with a focus on providing "leave nothing behind" treatments for vascular diseases. Acotec has developed advanced technologies, notably in drug-coated balloons and thrombus aspiration catheters. Their commercialized product, the Semi-compliant PTCA Balloon (YAN), is designed to improve myocardial perfusion by dilating stenosed coronary arteries or bypass vessels. The company operates primarily from Mainland China, Europe, and other regions, with a significant portion of its revenue generated internationally.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Obsidio, Inc. is a medical device company based in Solana Beach, California, founded in 2018. The company specializes in developing shear-thinning hydrogel biomaterial technology, which is utilized to create therapeutic devices and universal gel embolization materials. This innovative technology allows for minimally invasive embolization procedures to effectively stop unwanted blood flow in vessels throughout the body. Obsidio's products are designed to address a variety of medical issues, including hemorrhage, aneurysms, and cancers, by providing targeted control of bleeding and occlusion of blood vessels. The company's biomaterial platform is applicable in interventional radiology and oncology, enabling precise and durable treatment solutions.

M.I.Tech develops, manufactures, and provides medical devices in the field of digestive endoscopy. It specializes in the fields of manufacturing, medical device and healthcare.

Baylis Medical Company specializes in high-technology medical devices, particularly within cardiology, endovascular, and oncology sectors. The company is renowned for its Radio Frequency Puncture System, which allows for controlled perforations in cardiac and vascular tissues, and is considered the gold standard for treating pulmonary atresia. In addition to developing innovative medical solutions, Baylis Medical has a robust history of importing and distributing products in the Canadian market, representing various manufacturers in cardiology, pain management, and radiology. The company is recognized for its commitment to providing state-of-the-art products and exceptional service, which has fostered a strong reputation within the medical community. Its product offerings include advanced transseptal platforms, guidewires, sheaths, and dilators, aimed at improving safety and efficacy in procedures such as atrial fibrillation ablation and mitral valve interventions.

DeVoro Medical Inc., established in 2018, is a medical device developer based in Fremont, California. The company specializes in creating innovative devices aimed at restoring blood flow, with a focus on treating peripheral artery and vein clots. Their proprietary technology enables swift clearance of diverse clot morphologies and vessel sizes, addressing the thrombectomy market's need for efficient blood flow restoration.

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, founded in 2017. The company is focused on developing a novel treatment aimed at stabilizing the growth of mid-sized abdominal aortic aneurysms and preventing their rupture. Nectero Medical's innovative approach involves delivering a compound with a stabilizing agent directly to the aneurysm site, which inhibits further breakdown of the vessel wall and strengthens it. This treatment enables patients to undergo earlier intervention safely, potentially delaying or eliminating the need for major endovascular or surgical repairs.

Append Medical is a medical technology company focused on developing an innovative transcatheter Left Atrial Appendage (LAA) closure system aimed at preventing strokes by reducing the risk of blood clots traveling to the brain. The company’s approach involves a uniquely designed system that eliminates the LAA through tissue invagination and suture closure, providing a simplified alternative to traditional implant-based LAA closures. This method is intended to minimize the presence of foreign materials at the closure site, thereby reducing device-related thromboembolism risks. Currently in the pre-clinical in-vivo trial phase, Append Medical operates within a market projected to grow significantly, with estimates suggesting the LAA closure market could reach $25 billion in the coming years. The company is also affiliated with MEDX Xelerator, a medtech incubator supported by several prominent organizations.

The Lumenis surgical laser division is a global leader in advanced medical laser equipment and surgical laser technology. Lumenis is a pioneer in the field of laser for surgery and its cutting-edge devices are being used by top medical professionals and facilities around the world. The company Provides Urology laser, Gynecology laser, ENT laser and more systems for medical applications.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

Saluda Medical Pty Ltd. is a medical device company specializing in the development of neuromodulation technologies for chronic neurological conditions. Founded in 2010 and based in Artarmon, Australia, with additional offices in the United States and the United Kingdom, Saluda Medical focuses on its innovative Evoke system. This investigational device employs a closed-loop spinal cord stimulation approach that continuously monitors the spinal cord's response to stimulation and adjusts treatment in real-time to optimize patient outcomes. By utilizing a unique dose-control platform, Saluda Medical aims to customize therapy based on individual neural responses, thereby improving the management of chronic pain, particularly in patients suffering from conditions such as neuropathic pain and chronic back pain.

InterVene, Inc. is a medical device company based in South San Francisco, California, specializing in innovative treatments for chronic venous insufficiency (CVI), particularly focusing on deep vein valve failure. Incorporated in 2011, the company develops catheter-based therapies aimed at restoring valvular competency in patients experiencing severe venous conditions. Its flagship product, the BlueLeaf™ Endovenous Valve Formation System, provides a non-implantable solution that enables physicians to create new vein valves using the patient's own vein wall tissue. By offering minimally invasive therapies, InterVene seeks to improve patient outcomes related to venous stasis ulcers and other symptoms associated with chronic venous disease.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Claret Medical, Inc. is a cardiovascular medical device company based in Santa Rosa, California, focused on developing cerebral vascular protection systems for transcatheter aortic valve implantation and other endovascular procedures. The company's flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris dislodged during these procedures, thereby reducing the risk of stroke. Additionally, Claret Medical offers small 6 French catheters that are inserted through an artery into the patient's right arm, guiding the system to the heart and effectively safeguarding the brain from embolic material during interventional procedures. Incorporated in 2009, Claret Medical aims to enhance patient safety and outcomes by preventing the entry of thrombus and debris into the cerebral vascular system during various cardiovascular interventions.

Cryterion Medical is a medical technology company based in Carlsbad, California, with additional offices in Montreal, Canada, and Wexford, Ireland. The company specializes in developing a single-shot cryoablation platform aimed at treating atrial fibrillation (AF). This innovative platform utilizes cryothermal energy to disrupt the irregular electrical signals responsible for AF. It features a next-generation balloon catheter, an advanced mapping catheter, a steerable sheath, and an enhanced console. Together, these components are designed to streamline procedural workflow, improve maneuverability, and facilitate positioning within complex anatomical structures, ultimately providing physicians with an effective solution for managing abnormal heart rhythms associated with atrial fibrillation.

RenovoRx, Inc. is a medical device company based in Los Altos, California, established in 2012. The company focuses on innovative solutions for the targeted delivery of therapeutic and diagnostic agents to specific sites within the peripheral vascular system. Its flagship product, RenovoCath, is an endovascular catheter designed for use in the visceral and peripheral vascular systems. RenovoRx has received FDA clearance for its RenovoCath RC120 and is actively introducing this technology to the clinical market. The company aims to improve therapeutic outcomes, particularly for cancer patients, through its proprietary Trans-Arterial Micro-Perfusion therapy platform, which allows for precise delivery of treatments directly to tumors while reducing potential toxicities associated with systemic therapies. Supported by a team of experienced management and a diverse Advisory Board of medical professionals, RenovoRx is committed to advancing its clinical development strategies and addressing high unmet medical needs in cancer treatment.

nVision Medical Corporation is a privately-held medical device company based in Saratoga, California, focused on advancing women's health innovation. Established in 2009, the company specializes in developing devices to assess and treat female infertility resulting from fallopian tube dysfunction. nVision's products are designed not only to detect conditions such as ovarian cancer and tube blockage but also to address the challenges faced in diagnosing and treating issues within the female reproductive tract. By concentrating on these critical areas, nVision aims to improve clinical outcomes and enhance the overall health of women. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

NxThera, founded in 2008 and headquartered in Maple Grove, Minnesota, specializes in the development of medical technologies for treating endourological conditions. The company's core technology involves convective water vapor energy, designed to deliver minimally invasive, thermal therapy for conditions such as benign prostatic hyperplasia (BPH), which affects over 32 million men in the U.S. As of April 30, 2018, NxThera operates as a subsidiary of Boston Scientific Corporation.

EMcision Ltd. was a medical device company that specialized in developing proprietary technologies based on radiofrequency (RF) for the surgical treatment of cancer patients. The company's notable products included the Habib EndoHPB, an endoscopic bipolar RF probe for ablating gastrointestinal tissue, and the Habib Endoblate, which targeted endoluminal ablation of inoperable gastrointestinal tumors. Additionally, EMcision offered the Habib VesCoag, an endovascular RF catheter designed for precise vascular occlusion, along with other devices such as the Habib 3Fr PerCoag and various bipolar RF devices for solid tumor ablation. EMcision marketed its products through a direct sales team in the United States and a network of distributors across multiple countries, including Canada, Germany, and the United Kingdom. Established in 1999 and headquartered in London, UK, with a branch in Montreal, Canada, the company aimed to enhance treatment options for cancer patients before ceasing operations.

Millipede Inc. is a medical device company based in Santa Rosa, California, focused on developing innovative percutaneous solutions for mitral and tricuspid valve repair. Incorporated in 2012, the company specializes in a catheter-based approach, creating a semi-rigid annuloplasty ring designed to address conditions such as mitral and tricuspid regurgitation. This technology aims to replicate the gold standard in valve repair by reducing the valve annulus diameter, thereby restoring leaflet coaptation and alleviating severe mitral regurgitation. As of January 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, enhancing its capacity to deliver effective treatment options for patients and healthcare providers worldwide.

Millipede Inc. is a medical device company based in Santa Rosa, California, focused on developing innovative percutaneous solutions for mitral and tricuspid valve repair. Incorporated in 2012, the company specializes in a catheter-based approach, creating a semi-rigid annuloplasty ring designed to address conditions such as mitral and tricuspid regurgitation. This technology aims to replicate the gold standard in valve repair by reducing the valve annulus diameter, thereby restoring leaflet coaptation and alleviating severe mitral regurgitation. As of January 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, enhancing its capacity to deliver effective treatment options for patients and healthcare providers worldwide.

Apama Medical, Inc. is a medical device company that specializes in catheter ablation technology for the treatment of atrial fibrillation (AF). Founded in 2009 and based in Campbell, California, the company offers a radiofrequency balloon catheter system designed to enhance the effectiveness of ablation procedures. This innovative system integrates multi-electrode technology, allowing for the delivery of energy in a manner that combines the advantages of both point-by-point and balloon-based ablation techniques. The system features built-in digital cameras, LED lights, and sensing electrodes, which facilitate real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical operates in the rapidly growing electrophysiology market, aiming to improve the detection and treatment of heart rhythm disorders. Since October 2017, the company has been a subsidiary of Boston Scientific Corporation.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.

Amphora Medical, Inc. is a Minnesota-based company that develops innovative medical devices aimed at treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is focused on creating a novel cystoscopic device that utilizes minimally invasive procedures to enhance bladder function. Amphora Medical's technology is designed to improve the quality of life for individuals suffering from OAB, offering a promising solution in the field of urology.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Neovasc Inc., a specialty medical device company headquartered in Richmond, Canada, develops, manufactures, and markets products for the cardiovascular marketplace globally. Its portfolio includes the Tiara technology, designed for the transcatheter treatment of mitral valve disease, and the Neovasc Reducer, which treats refractory angina. The Reducer has been commercially available in Europe since 2015 but is not yet approved in the United States. Additionally, Neovasc offers pericardial tissue processing and vascular product development services to industry partners.

The LumenR Tissue Retractor System is currently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Cosman Medical specializes in the development and manufacturing of radiofrequency (RF) ablation systems, including generators, electrodes, and cannulae. The company provides a wide array of products designed for use in neurosurgery, interventional anesthesiology, and podiatry. RF nerve ablation has been utilized in medical practice for over 60 years, effectively treating a variety of chronic pain conditions such as back and neck pain, facet joint dysfunction, and sciatica. Additionally, it addresses severe, intractable pain associated with end-stage cancer and other complex pain syndromes. In podiatry, RF technology is employed to alleviate pain from conditions like plantar fasciitis and Morton's Neuroma. Furthermore, in the field of functional neurosurgery, RF is applied to manage movement disorders including Parkinson's Disease and essential tremor.

NxThera, founded in 2008 and headquartered in Maple Grove, Minnesota, specializes in the development of medical technologies for treating endourological conditions. The company's core technology involves convective water vapor energy, designed to deliver minimally invasive, thermal therapy for conditions such as benign prostatic hyperplasia (BPH), which affects over 32 million men in the U.S. As of April 30, 2018, NxThera operates as a subsidiary of Boston Scientific Corporation.

TVA Medical, Inc. is a medical device company based in Austin, Texas, specializing in the development and manufacturing of catheter-based equipment for treating end-stage renal disease and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on innovative, minimally invasive therapies, notably its everlinQ endoAVF system, which creates an arteriovenous fistula using an endovascular approach to facilitate hemodialysis for patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. As of July 2018, TVA Medical operates as a subsidiary of Becton, Dickinson and Company.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

American Medical Systems, a subsidiary of Endo Pharmaceutical based in Minnetonka, Minnesota, specializes in medical devices and procedures aimed at treating incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse, and other pelvic disorders affecting both men and women. These conditions can severely impact an individual's quality of life and social interactions. In recent years, there has been a notable increase in the number of patients seeking treatment due to longer life expectancies, heightened expectations for quality of life, and increased awareness of available treatment options. The company's offerings focus on reducing or eliminating the debilitating effects of these disorders, frequently utilizing minimally invasive therapies. In 2010, American Medical Systems' products were utilized to treat over 340,000 patients.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Xlumena, Inc. is a medical technology company specializing in the development of image-guided therapeutic endoscopy products. Founded in 2008 and located in Mountain View, California, the company focuses on creating innovative solutions for gastrointestinal and biliary conditions. Its product offerings include the AXIOS Stent and Delivery System, which is designed for treating pancreatic pseudocysts, and the NAVIX Access Device, also targeting this condition. Additionally, Xlumena develops a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a solution for hiatal hernia repair performed through the gastrointestinal lumen. In 2015, Xlumena became a subsidiary of Boston Scientific Corporation, further enhancing its capabilities in the medical device field.

InterVene, Inc. is a medical device company based in South San Francisco, California, specializing in innovative treatments for chronic venous insufficiency (CVI), particularly focusing on deep vein valve failure. Incorporated in 2011, the company develops catheter-based therapies aimed at restoring valvular competency in patients experiencing severe venous conditions. Its flagship product, the BlueLeaf™ Endovenous Valve Formation System, provides a non-implantable solution that enables physicians to create new vein valves using the patient's own vein wall tissue. By offering minimally invasive therapies, InterVene seeks to improve patient outcomes related to venous stasis ulcers and other symptoms associated with chronic venous disease.

Iogyn, Inc. is a medical device start-up company located in Cupertino, California. The Company has developed the Symphion System, designed for endoscopically-controlled Radiofrequency bi-polar resection and removal of soft tissue, such as polyps, myomas and prostate adenomas, requiring endoscopic visualization under continuous flow conditions.

StarMedTec is a globally recognized manufacturer of medical laser systems, specializing in the development, production, and marketing of advanced laser solutions. The company's product offerings cater to various medical disciplines, including urology, gynecology, gastroenterology, ear, nose, and throat (ENT), pneumology, and general surgery. By providing innovative laser surgery solutions, StarMedTec enhances the capabilities of healthcare professionals and contributes to improved patient outcomes across these fields.

Sensible Medical Innovation Ltd, established in 2007 and based in Netanya, Israel, specializes in developing medical radar technology for monitoring and imaging. Its flagship product, ReDS, is designed to track and manage lung fluid in patients with heart failure and other fluid-related health issues, providing accurate and actionable data to healthcare professionals. This non-invasive solution aims to improve patient quality of life and potentially reduce hospital readmissions.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.

BaroSense is focused on developing and commercializing innovative medical devices aimed at addressing obesity, a significant healthcare challenge in the United States. The company aims to provide safe, simple, and effective alternatives to surgical treatments for obesity, catering to individuals who require assistance beyond traditional dieting methods and wish to avoid extensive and irreversible surgical options. BaroSense's product offerings include minimally invasive therapeutic procedures and devices, such as a trans-oral endoscopic restrictive implant system, designed to facilitate weight loss in a less invasive manner.

Bard Electrophysiology, a division of C. R. Bard, Inc., specializes in the development and delivery of devices for the diagnosis and treatment of cardiac arrhythmias. The company provides a comprehensive product portfolio that includes advanced radiofrequency (RF) ablation and mapping catheters, diagnostic catheters, computer-based electrophysiology mapping and recording systems, temporary pacing electrodes, and vascular and cardiac access devices. With over a century of experience in healthcare innovation, Bard Electrophysiology is committed to advancing medical technology and improving patient outcomes through its dedication to high-quality products and exceptional support. The company aims to enhance the capabilities of healthcare providers worldwide by delivering effective solutions in electrophysiology.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

Vessix Vascular, Inc. is a privately-held medical device company focused on developing innovative catheter-based technologies. The company's primary product, the ZCath® System, utilizes radiofrequency balloon catheter technology to treat high blood pressure by targeting and deadening nerves near the kidneys. This approach aims to provide an effective solution for reducing plaque in peripheral leg arteries. Vessix Vascular is currently in the pre-revenue stage and has achieved a CE Mark for its initial product, indicating its compliance with European health and safety standards.

Rhythmia Medical, Inc., founded in 2016, specializes in developing innovative medical devices aimed at treating cardiac arrhythmias. The company's primary focus lies in creating a state-of-the-art 3D mapping system designed to enhance catheter ablation procedures used to treat tachy-arrhythmias like atrial fibrillation. Rhythmia Medical aims to improve the visualization and navigation aspects of these critical procedures, thereby potentially enhancing patient outcomes.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

Atritech is a private medical technology company based in Minneapolis, Minnesota, founded in 2000. The company specializes in developing minimally invasive technologies aimed at preventing strokes related to atrial fibrillation. Their flagship product, the WATCHMAN Left Atrial Appendage Closure Technology, is designed to offer a permanent alternative to long-term anticoagulation therapy for patients with non-valvular atrial fibrillation who are at risk of stroke. The device works by closing off the left atrial appendage, preventing harmful blood clots from entering the bloodstream and causing strokes or other complications. The WATCHMAN Device has been CE Marked and is available in many markets outside the United States, while it is currently under investigation in the U.S.

Intelect Medical, Inc. is an early-stage medical device company dedicated to the development and commercialization of deep brain stimulation (DBS) therapies aimed at improving the lives of patients with disabilities resulting from stroke and traumatic brain injury. The company specializes in creating an implantable neuromodulation system designed to facilitate recovery in these patient populations. Through its innovative approach, Intelect Medical seeks to address significant medical needs and enhance therapeutic options for individuals affected by these conditions.

Sadra Medical is dedicated to developing innovative therapies for treating aortic valve disease, focusing on minimally invasive alternatives to traditional surgical valve replacement. The company aims to improve patient care and expand treatment options for a broader range of patients by reducing the risks and morbidity associated with open-heart surgery. Sadra Medical's key product is the Lotus valve, a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure, along with the Lotus delivery catheter designed for precise placement of the valve. As a subsidiary of Boston Scientific, Sadra Medical addresses a significant unmet clinical need, as only a small percentage of the estimated 3 million people in the U.S. with aortic valve stenosis receive treatment through current standard procedures.

Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.

Sadra Medical is dedicated to developing innovative therapies for treating aortic valve disease, focusing on minimally invasive alternatives to traditional surgical valve replacement. The company aims to improve patient care and expand treatment options for a broader range of patients by reducing the risks and morbidity associated with open-heart surgery. Sadra Medical's key product is the Lotus valve, a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure, along with the Lotus delivery catheter designed for precise placement of the valve. As a subsidiary of Boston Scientific, Sadra Medical addresses a significant unmet clinical need, as only a small percentage of the estimated 3 million people in the U.S. with aortic valve stenosis receive treatment through current standard procedures.

Intelect Medical, Inc. is an early-stage medical device company dedicated to the development and commercialization of deep brain stimulation (DBS) therapies aimed at improving the lives of patients with disabilities resulting from stroke and traumatic brain injury. The company specializes in creating an implantable neuromodulation system designed to facilitate recovery in these patient populations. Through its innovative approach, Intelect Medical seeks to address significant medical needs and enhance therapeutic options for individuals affected by these conditions.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

CryoCor, Inc. is a medical technology company headquartered in San Diego, California developing products that use cryogenic technology to treat cardiac rhythm disorders called arrhythmias. Cardiac cryoablation is a non-surgical, minimally-invasive procedure in which a cardiologist inserts a catheter into a blood vessel in the leg of an afflicted individual and advances it into the heart. Once it reaches the targeted cardiac tissue, the catheter tip temperature is lowered to approximately -90°C — thereby blocking the conduction of the abnormal signals causing the heart to beat inappropriately and restoring its function to normal. The CryoCor™ Cardiac Cryoablation System consists of a cryoablation catheter that is connected to an articulating arm mounted on the company’s refrigeration console. To facilitate catheter placement, the System can be used in conjunction with CryoCor introducer sheaths. The System has been approved for use in Europe and has been commercially available there since 2002. CryoCor's European activities are managed by its wholly-owned subsidiary in Cologne, Germany which directs the company's marketing, sales and post-market clinical activities. The CryoCor Cardiac Cryoablation System is currently in use at multiple medical centers throughout Europe.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. It focuses on creating innovative miniature implants and medical devices to improve patient monitoring. The company's flagship products include RemonCHF, which is designed to monitor the hemodynamic status of patients suffering from congestive heart failure, and RemonAAA, a device that tracks pressure levels following endograft procedures in patients with abdominal aortic aneurysms. Through its advanced monitoring solutions, Remon Medical Technologies aims to enhance patient care and outcomes in critical healthcare scenarios.

Intelect Medical, Inc. is an early-stage medical device company dedicated to the development and commercialization of deep brain stimulation (DBS) therapies aimed at improving the lives of patients with disabilities resulting from stroke and traumatic brain injury. The company specializes in creating an implantable neuromodulation system designed to facilitate recovery in these patient populations. Through its innovative approach, Intelect Medical seeks to address significant medical needs and enhance therapeutic options for individuals affected by these conditions.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

EndoTex Interventional Systems, Inc. is a development stage medical device company based in Cupertino, California, founded in 1995. The company specializes in creating less-invasive medical devices aimed at addressing conditions within the vascular system, with a particular focus on treating carotid artery disease. EndoTex is recognized for its innovative interventional vascular therapeutic solutions. As of January 2007, it operates as a subsidiary of Boston Scientific Corp.

Health Hero Networks, founded in 1988 and headquartered in Palo Alto, California, specializes in developing technology solutions for remote health monitoring and management. The company offers personalized daily monitoring programs, patient education resources, and interfaces like the Health Buddy system, which facilitates communication between patients at home and care providers. Their services cater to hospitals, health plans, government organizations, disease management companies, pharmaceutical companies, and clinical trial entities. As of December 2007, Health Hero Networks operates as a subsidiary of Robert Bosch GmbH.

Sadra Medical is dedicated to developing innovative therapies for treating aortic valve disease, focusing on minimally invasive alternatives to traditional surgical valve replacement. The company aims to improve patient care and expand treatment options for a broader range of patients by reducing the risks and morbidity associated with open-heart surgery. Sadra Medical's key product is the Lotus valve, a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure, along with the Lotus delivery catheter designed for precise placement of the valve. As a subsidiary of Boston Scientific, Sadra Medical addresses a significant unmet clinical need, as only a small percentage of the estimated 3 million people in the U.S. with aortic valve stenosis receive treatment through current standard procedures.

Solace Therapeutics, Inc. is a medical device company based in Framingham, Massachusetts, that specializes in developing non-surgical, office-based treatments for common bladder disorders, including stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS). The company’s flagship product, the Vesair Bladder Control System, is a lightweight device designed to float within the urinary bladder, effectively addressing involuntary urinary leakage without the need for anesthesia or surgical intervention. Solace Therapeutics aims to enhance patients' quality of life by offering a treatment option that minimizes the side effects often associated with traditional drug and surgical therapies, allowing for a reversible and less intrusive approach to bladder health.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

Guidant Corporation specializes in the design and manufacture of medical devices for cardiovascular care. Operating as part of Boston Scientific and Abbott Labs, the company focuses on products for cardiac-rhythm management and the treatment of coronary artery disease. Its offerings include artificial cardiac pacemakers, implantable cardioverter-defibrillators, stents, catheters, and devices for heart-failure therapy. Headquartered in Indianapolis, Indiana, Guidant aims to improve the quality of life for patients with heart diseases and enhance clinical outcomes for physicians. Founded in 1994, the company has established itself as a key player in the cardiovascular medical device industry.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

Adiana, Inc. is a company based in Redwood City, California, founded in 1997, that focuses on the development and testing of transcervical sterilization systems for permanent birth control. The company's main product, Complete TCS, comprises a radiofrequency generator, delivery catheter, and implantable matrix, designed to occlude the fallopian tubes and prevent pregnancy. Adiana aims to provide a novel, non-incisional alternative to traditional tubal ligation, offering women a solution that minimizes the side effects and complications associated with other contraceptive methods. As of 2007, Adiana operates as a subsidiary of CYTYC Corp.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for central nervous system diseases, particularly acute ischemic stroke. Founded in 2000, the company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Its innovative treatment approach involves a miniature electrode implanted in the roof of the mouth through a minimally invasive procedure performed under local anesthesia. BrainsGate's key product is an ischemic stroke system that delivers targeted stimulation to the SPG, with the aim of improving outcomes for stroke patients. The company has conducted significant clinical trials, including a pivotal study with 300 participants that demonstrated the safety and efficacy of its treatment. Currently, BrainsGate is advancing the ImpACT-24b trial, a multinational randomized study assessing the treatment's effectiveness within a critical 24-hour window following stroke onset.

3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

CryoVascular Systems is a medical technology company that specializes in developing and manufacturing innovative therapies for the treatment of peripheral vascular and cardiovascular diseases. The company is known for its proprietary PolarCath Peripheral Dilatation System, which employs liquid nitrous oxide to precisely cool diseased arteries during balloon angioplasty. This process, referred to as CryoPlasty, aims to revascularize the artery and significantly reduce the incidence of restenosis, a common complication that often necessitates repeat angioplasty procedures or surgery. The PolarCath system addresses the high repeat procedure rates associated with traditional balloon angioplasty and stent technologies, particularly for the femoral-popliteal arteries. Founded in 1997 and headquartered in Los Gatos, California, CryoVascular Systems was acquired by Boston Scientific Corporation in 2005.

Advanced Stent Technologies designs and develops stents and stent delivery systems for the treatment of atherosclerosis at bifurcations in the coronary vasculature. The company’s flagship product, the SLK-View stent and delivery system, is used for treating diseased bifurcations by providing stability to the main artery while maintaining access to the side branch vessel. Advanced Stent Technologies was founded in 1997 and is based in Pleasanton, California.

VisionCare Ophthalmic Technologies, Inc., established in 1997 and headquartered in Saratoga, California, is a specialty medical device company dedicated to improving vision for individuals with untreatable retinal disorders. The company focuses on the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices. Its flagship product, the Implantable Miniature Telescope (IMT), is an FDA-approved device designed to enhance vision in patients with end-stage age-related macular degeneration (AMD). The IMT is integral to the CentraSight treatment program, which guides patients through diagnosis, surgical evaluation, and postoperative care. VisionCare's mission is to restore visual functionality and improve quality of life for individuals with untreatable retinal disorders, primarily focusing on End-Stage AMD, the leading cause of blindness in older Americans.

REVA Medical, Inc. is a medical device company based in San Diego, California, established in 1998. The company specializes in developing and commercializing polymer-based bioresorbable products for vascular applications. Its primary offerings include the Fantom Encore, a bioresorbable vascular scaffold designed for the treatment of coronary artery disease, and the MOTIV scaffold for below-the-knee peripheral artery disease. REVA Medical's products utilize proprietary tyrosine-derived polymer technologies that support the healing of arteries while eventually dissolving in the body, thus restoring natural function. The Fantom Encore is marketed in several European countries, including Germany, Switzerland, and Italy. Initially founded as MD3, Inc., the company rebranded to REVA Medical, Inc. in March 2002.

3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

Advanced Bionics Corporation is a developer and manufacturer of implantable neurostimulation devices, specializing in cochlear implants that restore hearing for the deaf. Founded in 1993 and headquartered in Valencia, California, the company also has offices in Rixheim, France, and Tokyo, Japan. Its innovative technology extends beyond hearing restoration, as it also focuses on alleviating chronic pain and treating various neurological conditions through the delivery of targeted electrical currents to specific nerve fibers.